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Abstract	
Objectives Acute	 pancreatitis	 (AP)	 can	 initiate	 systemic	 complications	 that	 require	 support	 in	critical	 care	 (CC).	 Our	 objective	 was	 to	 utilize	 the	 unified	 national	 health	 record	 to	define	 the	 epidemiology	 of	 AP	 in	 Scotland,	with	 a	 specific	 focus	 on	 deterministic	 and	prognostic	factors	for	CC	admission	in	AP.		
Setting Health	boards	in	Scotland	(n=4).	
Participants	We	included	all	individuals	in	a	retrospective	observational	cohort	with	at	least	one	episode	of	AP	(ICD10	code	K85)	occurring	in	Scotland	from	1st	April	2009	to	31st	March	2012.	3340	individuals	were	coded	as	AP.	
Methods Data	 from	 sixteen	 sources,	 spanning	 general	 practice,	 community	 prescribing,	 A&E,	hospital	in-patient,	critical	care,	and	mortality	registries	were	linked	by	a	unique	patient	identifier	in	a	national	safe	haven.	Logistic	regression	and	gamma	models	were	used	to	define	 independent	 predictive	 factors	 for	 severe	 AP	 (sAP)	 requiring	 CC	 admission	 or	leading	to	death.	
Results 2053	individuals	(61.5%	(95%CI	59.8,	63.2%))	met	the	definition	for	true	AP	(tAP).	368	patients	 (17.9%	of	 tAP	 (95%CI	16.2,	 19.6%))	were	 admitted	 to	 CC.	 Predictors	 of	 sAP	were:	pre-existing	angina	or	hypertension,	hypocalcaemia,	and	age	30-39	years,	if	type	2	 diabetes	mellitus	was	 present.	 The	 risk	 of	 sAP	was	 lower	 in	 patients	with	multiple	previous	 episodes	 of	 AP.	 In-hospital	 mortality	 in	 tAP	 was	 5.0%	 (95%CI	 4.1,	 5.9%)	overall,	and	21.7%	(95%CI	19.9,	23.5%)	in	those	with	tAP	necessitating	CC	admission.		
Conclusion National	 record-linkage	 analysis	 of	 routinely	 collected	 data	 constitutes	 a	 powerful	resource	 to	 model	 CC	 admission	 and	 prognosticate	 death	 during	 AP.	 Mortality	 in	patients	with	AP	who	require	CC	admission	remains	high.		
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Strengths and Limitations of this Study	
• National	 record-linkage	 analysis	 of	 routinely	 collected	 data	 constitutes	 a	powerful	 resource	 to	 model	 critical	 care	 admission	 and	 prognosticate	 death	during	critical	illness.	
• This	 project	 brought	 together	 sixteen	 electronic	 data	 sources	 through	 a	 new	record-linkage	model	for	Scotland	and	was	at	the	forefront	of	the	development	of	the	National	Data	Safe	Haven	in	Scotland	
• For	 individuals	 with	 AP	 who	 are	 not	 severely	 ill,	 electronically-formatted	routinely	recorded	clinical	data	is	less	comprehensive	and	this	may	have	led	to	a	negative	 reporting	 bias	 for	 events	 not	 sufficiently	 severe	 to	 need	 critical	 care	admission.	
• Although	we	specifically	 conducted	a	data	accuracy	pilot,	 comparing	electronic	records	with	 hand-written	notes	 in	 four	 separate	 study	 sites,	 certain	 variables	are	 likely	 to	 be	 more	 accurate,	 for	 example	 automatically-retrieved	Wardwatcher™	 critical	 care	 data,	 than	 others	 for	 example	 comorbidity	 and	hospital	immediate	discharge	summaries.		
• Although	specific	risk	factors	can	be	identified	which	increase	risk	of	developing	multiple	 organ	 dysfunction	 in	 AP,	 it	 is	 not	 pragmatic	 or	 straightforward	 to	predict	which	individual	patients	are	likely	to	require	critical	care	based	on	their	routinely-collected	medical	data.				
Keywords	Acute	pancreatitis;	severity	stratification;	critical	care;	organ	failure;	multiple	organ	dysfunction	syndrome;	national	record	linkage;	safe	haven.				 	
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Introduction	
Background/rationale	Acute	 pancreatitis	 (AP)	 is	 an	 inflammatory	 disease	 of	 the	 pancreas	 with	 potentially	devastating	consequences	for	those	who	suffer	a	severe	attack.	Individual	estimates	of	the	incidence	of	AP	range	from	10	to	78	per	100	000	per	year1-6.	AP	was	found	to	be	the	most	 common	 reason	 for	hospitalization	with	 a	 gastrointestinal	 disorder	 in	 the	US	 in	20127.	 The	 estimated	 financial	 cost	 for	 AP-related	 care	 in	 the	 US	 in	 2004	 was	 $3.7	billion,	 with	 AP	 resulting	 in	 277	 000	 hospital	 admissions	 and	 475	 000	 ambulatory	visits8.	The	financial	cost	of	treating	AP	in	the	UK	has	been	estimated	at	£200	million	per	year9.			In	approximately	20%	of	patients	with	AP,	severe	complications	can	develop	which	may	evolve	 into	multiple	 organ	dysfunction	 syndrome	 (MODS)	 requiring	 critical	 care	 (CC)	support	 in	 high	 dependency	 (HDU)	 or	 intensive	 treatment	 units	 (ITU)10	11.	 AP-MODS	usually	 occurs	 rapidly,	 and	 features	 of	 AP-MODS	 may	 be	 present	 at	 the	 time	 of	presentation	 to	hospital12.	Between	2008	and	2010,	5%	of	all	 available	 intensive	care	beds	in	Scotland	were	taken	up	by	patients	with	AP9;	in	tertiary	referral	centres	ITU	bed	occupancy	 may	 reach	 9%13.	 The	 epidemiological	 risk	 factors	 for	 developing	 organ	dysfunction	amongst	individuals	with	AP	are	not	known	at	present.	This	knowledge	will	be	important	and	useful	to	identify	high-risk	patients	by	enhancing	the	stratification	of	disease	 severity,	 and	 to	 influence	 treatment	 decisions,	 plan	 healthcare,	 allocate	resources	 and	 inform	 trial	 design.	 Therefore,	 there	 exists	 a	 need	 to	 understand	 and	identify	 risk	 factors	 for	 progression	 to	 AP-MODS	 based	 on	 laboratory	 and	 clinical	information	leading	up	to,	and	at	the	time	of	acute	presentation	to	hospital.		The	 Farr	 Institute14	 was	 conceived	 with	 the	 goal	 of	 creating	 a	 unified	 healthcare	informatics	 infrastructure	 to	 allow	 interested	 parties	 from	 government,	 academia,	industry,	healthcare	providers	and	other	related	organisations	utilise	linked	electronic	healthcare	 data	 on	 a	 national	 scale	 in	 a	 secure,	 confidential	 and	 streamlined	way	 for	medical	research	within	the	UK.	Given	the	substantial	healthcare	burden	of	AP,	the	need	for	 improved	 understanding	 and	 treatment	 of	 AP,	 and	 the	 considerable	 interest	 in	development	of	novel	therapies	for	AP	by	us15	and	others,	the	aim	of	this	study	was	to	
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harness	the	power	of	the	Farr	Institute	capabilities	to	elucidate	the	epidemiology	of	AP	with	a	focus	on	defining	the	risk	factors	for	the	development	of	organ	failure	in	AP.	
Objectives	Our	specific	objectives	were	to	use	the	Farr	Institute	infrastructure	to:	1. Characterize	the	epidemiology	of	AP	in	Scotland	2. Define	the	determinants	of	admission	to	CC	and/or	death	in	AP	3. Describe	the	morbidity,	length	of	critical	care	stay,	organ	support	and	mortality	of	patients	with	AP	admitted	to	CC.	
Methods	
Study	design	We	undertook	a	retrospective	observational	cohort	study	of	 linked	healthcare	records	from	sixteen	electronic	data	sources	in	Scotland.	
Project	structure	and	Study	management	The	 collaborative	 core	 project	 team	 consisted	 of	 a	 project	 manager	 (PJ),	 clinician	scientists	 with	 expertise	 in	 AP	 (DJM,	 CS),	 an	 epidemiologist	 and	 statistician	 from	industry	 (UG,	 AL),	 national	 healthcare	 data	 expertise	 (CG,	 ADM,	 FS),	 data	 managers,	clinical	information	governance	(HW)	and	clinical	statistics	and	epidemiology	expertise	(LC,	 PTD).	 A	 project	 board	 (including	 lay	membership)	met	 quarterly	 to	 oversee	 the	project.	 The	 study	 protocol	 and	 analysis	 plan	were	 agreed	 in	 advance	 by	 the	 project	board.	
Ethical	approval,	patient	confidentiality	and	data	security	We	obtained	approvals	from:	National	Services	Scotland,	Privacy	Advisory	Committee;	National	Research	Ethics	Service;	National	Research	and	Development	Office;	the	local	Research	 and	 Development	 Office	 for	 each	 Health	 Board;	 NHS	 Board	 Caldicott	Guardians,	 via	 the	 Caldicott	 Guardians’	 National	 Scrutiny	 Process;	 Scottish	 Intensive	Care	 Society	 Audit	 Group	 (SICSAG)	 Steering	 Group;	 and	 General	 Practitioners	 (as	Caldicott	Guardians).	The	study	adhered	to	strict	information	governance	and	security	protocols.	 All	 primary	 data	 was	 held	 within	 the	 NHS	 Scotland	 Information	 Services	Division	 (ISD)	 National	 Safe	 Haven	with	 access	 restricted	 to	 two	 named	 statisticians	
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from	University	of	Dundee	 (LC,	PTD).	 Industry	partners	did	not	have	sight	of	patient-level	data	at	any	stage.	
Setting	and	data	sources	The	study	cohort	consisted	of	all	patients	who	had	a	general	or	acute	inpatient	or	day	case	 record	 of	 acute	 pancreatitis	 in	 any	 coding	 field,	 coded	 as	 K85	 under	 ICD10	K85	(including	K85.0	 Idiopathic	 acute	 pancreatitis;	 K85.1	Biliary	 acute	 pancreatitis;	 K85.2	Alcohol	induced	acute	pancreatitis;	K85.3	Drug	induced	acute	pancreatitis;	K85.8	Other	acute	pancreatitis;	K85.9	Acute	pancreatitis,	unspecified),	occurring	in	any	of	four	NHS	Health	Board	areas	 in	Scotland	between	1st	April	2009	and	31st	March	2012.	The	 first	episode	 for	 any	 one	 individual	 occurring	 in	 that	 time	 period	was	 taken	 as	 the	 index	episode.	 The	 combined	 total	 population	 of	 the	 four	 Health	 Boards	 was	 2	 063	 511	(48.9%	of	the	population	of	Scotland	aged	18	years	old	and	over)	at	the	midpoint	of	the	study,	 and	 included	 large	 conurbations	 and	 rural	 areas.	 For	 each	 patient,	 data	 were	collected	 from	 Accident	 and	 Emergency	 attendances	 (A&E2	 database),	 Scottish	Morbidity	Record	00	(SMR00)	Outpatient	attendances,	SMR01	(General/Acute	inpatient	and	 day	 cases),	 SMR04	 (Mental	 Health	 inpatient	 and	 day	 cases),	 SMR99	 (Death	registrations),	 Prescribing	 Information	 System	 (PIS,	 primary	 care	 prescribing	 and	dispensing),	 SICSAG	 (critical	 care),	 SCI	 Stores	 (laboratory	 test	 results),	 and	 general	practice	data.	Data	were	linked	within	the	National	Safe	Haven	by	an	approved	indexing	process	based	on	a	unique	patient	identifier	(the	CHI	number).	There	were	no	exclusion	criteria.	A	pilot	study	was	performed	to	assess	the	coding	accuracy	of	AP	in	SMR01.		
Definitions	and	categories	Acute	 pancreatitis	 (AP)	 was	 defined	 as	 occurring	 when	 any	 elective	 or	 emergency	admission	was	coded	as	ICD10	K85	in	any	diagnosis	field.	To	account	for	inaccuracies	of	coding,	True	AP	(tAP)	was	predefined	as	a	subset	of	AP	as:	upper	abdominal	pain	with	or	 without	 nausea	 or	 vomiting	 at	 presentation	 in	 the	 clinical	 records	 and	 a	 serum	amylase	or	lipase	result	greater	than	3	times	the	upper	limit	of	the	reference	range	for	that	laboratory;	or	CT	evidence	of	AP	alone.	We	predefined	severe	AP	(sAP)	as	a	subset	of	tAP	as:	tAP	requiring	admission	to	CC	as	part	of	the	same	episode,	or	tAP	resulting	in	death	during	that	hospital	episode.	Critical	care	was	defined	as	either	or	both	Level	2	or	Level	3	inpatient	care,	also	known	as	high-dependency	(HDU)	and	intensive	treatment	units	 (ITU)	 respectively.	 Aetiology	 of	 AP	 was	 defined	 at	 two	 levels:	 1)	 in	 the	 entire	
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cohort,	 AP	 was	 attributed	 to	 gallstones	 if	 this	 (or	 a	 related	 diagnosis,	 for	 example	cholecystectomy)	was	recorded	in	any	coding	position;	the	remainder	was	regarded	as	non-gallstone	 AP;	 2)	 aetiology	 recorded	 explicitly	 in	 hospital	 or	 GP	 records	 as	gallstones,	 alcohol	 or	 other	 less	 common	 causes.	 A	GP	 visit	was	 defined	 as	 a	 patient-practice	 interaction	 recorded	 as	 a	 visit	 event	 in	 GP	 records,	 without	 being	 able	 to	differentiate	between	an	actual	medical	consultation	and	other,	 for	example	obtaining	results,	visiting	the	practice	nurse	or	getting	a	repeat	prescription.	The	day	of	hospital	admission	was	defined	as	day	zero,	and	the	next	day	after	hospital	admission	as	day	1	and	so	on.	Overall	hospital	mortality	was	defined	as	death	during	a	single	episode	of	AP	occurring	prior	to	hospital	discharge.	Overall	90-day	mortality	was	defined	as	any	death	occurring	within	90	days	of	the	first	day	of	an	episode	of	AP.				
Variables	The	 primary	 outcome	 of	 interest	was	 the	 development	 of	 sAP	 (admission	 to	 CC,	 tAP	death).		Secondary	outcomes	of	interest	were:	length	of	hospital	stay	in	days,	length	of	CC	stay	 in	hours	and	days,	maximum	number	of	organs	supported,	 renal	 replacement	therapy,	 ventilator	 dependence,	 duration	 of	 enteral	 nutrition,	 hospital	 acquired	infection	 and	 death	 among	 those	 with	 sAP	 admitted	 to	 CC.	 Potential	 risk	 factors	included	 patient	 demographics,	 measures	 of	 socioeconomic	 deprivation	 (using	 the	Scottish	Index	of	Multiple	Deprivation16,	SIMD),	aetiology	of	AP,	laboratory	and	clinical	data	 at	 the	 time	 of	 presentation	 to	 hospital,	 history	 of	 medication	 use	 (prior	 to	 AP	presentation),	and	clinical/disease	history	up	to	the	time	of	AP	presentation,	the	latter	two	being	obtained	from	patients	primary	care	records	in	the	12	month	period	prior	to	the	index	episode.	Calcium	values	were	corrected	for	serum	albumin	concentration.		
Record	Linkage	Data	were	linked	using	established	probability	and	deterministic	matching	techniques17	based	 on	 the	 Howard	 Newcombe	 principles18.	 Linkage	 was	 undertaken	 by	 a	 trusted	third	 party.	 A	 population	 spine,	 which	 contained	 the	 personal	 identifiers	 of	 all	individuals	who	have	been	in	contact	with	NHS	Scotland,	was	used	as	an	intermediary	linkage	tool.	The	process	outlined	was	based	on	the	principles	of	data	linkage	outlined	in	 the	 Scottish	 Informatics	 Programme	 (SHIP)	 blueprint19.	 The	 steps	 of	 the	 process	were:	the	indexing	team	were	supplied	the	CHI	number	of	each	of	the	cohort	members	
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by	a	single	data	provider,	for	which	they	generated	a	different	record	ID	number	across	the	range	of	datasets.	Each	data	provider	received	a	file	back	with	a	list	of	patient	CHI	numbers	and	unique	person	index	ID	numbers	specific	to	that	dataset,	generated	by	the	indexing	 team.	 The	 data	 provider	 then	 attached	 the	 received	 index	 ID	 number	 to	 the	remaining	content	of	the	dataset	to	be	provided	for	linkage	and	sent	this	to	the	research	coordinator.	 The	 research	 coordinator	 sent	 the	 file	 to	 the	 linkage	 agent,	 which	 is	 an	automated	 computer	programme.	The	 linkage	 agent	 received	2	 files	 -	 all	 the	datasets	including	 unique	 person	 ID	 numbers,	 plus	 a	 master	 control	 file	 containing	 a	 master	person	ID	and	unique	person	index	ID	numbers	for	the	entire	dataset.	The	linkage	agent	replaced	all	the	dataset	unique	person	ID	numbers	with	the	master	person	ID	number	on	 each	 of	 the	 content	 data	 files.	 The	person	 analyzing	 the	data	 had	 access	 to	 all	 the	records	 belonging	 to	 an	 individual	 across	 all	 the	 datasets	 without	 sight	 of	 personal	identifiers.	
Statistical	methods	Descriptive	 analyses	 were	 performed	 according	 to	 standard	 principles	 using	 SAS	 9.3	and	following	the	STROBE	criteria20.	Categorical	variables	were	reported	as	counts	and	percentages	 of	 the	 number	 of	 valid	 cases.	 	 Continuous	 variables	 were	 described	 by	either	 mean	 and	 standard	 deviation	 (for	 plausibly	 Normal	 data)	 or	 medians	 and	quartiles	(non-Normal	data).	Between	group	comparisons	for	univariate	analyses	were	by	 independent	 samples	 t-test	 or	 Mann-Whitney	 U-test	 for	 Normal	 data	 and	 non-Normal	 data	 respectively.	 Differences	 in	 proportions	 were	 tested	 by	 the	 χ2	 test.	 To	correct	 for	 extreme	 outliers	 in	 an	 otherwise	 Normally	 distributed	 dataset,	 the	 5%	trimmed	 mean	 was	 used	 where	 stated;	 this	 value	 is	 the	 arithmetic	 mean	 of	 data	between	 the	 5th	 and	 95th	 centile.	 Time-to-event	 variables	 were	 summarized	 using	medians	 and	 quartiles.	 Factors	 predicting	 the	 development	 of	 sAP	 in	 the	 tAP	 cohort	were	modeled	by	 logistic	regression	with	sAP	as	binary	dependent	variable.	Variables	were	 selected	 on	 the	 basis	 of	 known	 clinical	 importance	 as	 well	 as	 backward	elimination	 to	 identify	 variables	 significant	 at	 the	 5%	 level.	 The	 final	model	was	 also	assessed	 for	 goodness-of-fit	 using	 Akaike’s	 Information	 Criterion	 (AIC).	 Interactions	between	variables	were	entered	and	assessed	by	adding	interaction	terms	in	the	model.	Predictive	performance	of	the	model	was	assessed	by	estimation	of	the	Area	under	the	ROC	curve	(AUROC)	and	calibration	assessed	with	the	Hosmer-Lemeshow	test.	The	final	
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model	for	prediction	was	based	on	the	largest	AUROC.	A	number	of	parametric	survival	models	were	applied	to	identify	factors	that	predict	death	during	the	CC	admission.	AIC	was	used	to	decide	on	which	model	was	optimal.	Model	selection	criteria	were	the	same	as	for	the	logistic	regression	model.		
Imputation	of	missing	data	For	 the	 logistic	 regression	model,	 where	 clinically	 important	 variables	 had	 less	 than	50%	missing	 values,	multiple	 imputation	was	used	 to	 ensure	 regression	 analysis	was	robust	 assuming	 data	 was	 missing	 at	 random	 (MAR).	 In	 practice,	 19%	 of	 calcium	measures	at	index	admission	were	imputed	along	with	35%	of	the	primary	care	flag	for	alcohol	dependency.		All	other	variables	in	the	models	were	100%	complete.			
Results	
Participants	and	univariate	analysis	3340	 individuals	were	 identified	 as	 having	 an	AP	 coded	hospital	 admission,	 of	which	2053	(61.5%)	met	the	case	definition	of	tAP	and	were	included	in	the	study.	Figure	1	shows	patient	flow	in	the	study.	The	incidence	of	an	AP-coded	hospital	admission	was	54.0	(95%	CI	41.1,	70.9)	per	100	000	per	year;	the	incidence	of	tAP	was	33.1	(95%	CI	24.4,	46.9)	per	100	000	per	year;	and	the	incidence	of	sAP	requiring	CC	admission	was	5.9	(95%	CI	3.4,	15.3)	per	100	000	per	year.	Demographic	characteristics	of	the	cohort	are	 shown	 in	 Table	 1.	 Gender	 distribution	 was	 approximately	 equal	 across	 all	categories	and	only	increased	marginally	towards	a	male	preponderance	for	those	with	sAP	admitted	to	critical	care.	The	mean	age	of	those	with	sAP	was	significantly	higher	than	those	who	did	not	develop	severe	disease.	Gallstones	were	co-recorded	in	43.8%	of	the	entire	 cohort	 coded	as	AP.	The	proportion	of	patients	with	gallstone	aetiology	AP	was	higher	for	females.	The	BMI	of	patients	admitted	to	CC	was	on	average	1.1	kg/m2	higher	 than	 the	 remainder	 of	 the	 tAP	 cohort.	 A	 disproportionate	 number	 of	 tAP	admissions	 (35.3%)	were	 from	the	most	socially	deprived	quintile;	 this	disproportion	was	similarly	observed	in	the	subset	with	sAP	(35.0%).	The	proportion	of	patients	with	tAP	 who	 develop	 sAP	 and	 the	 proportion	 of	 those	 requiring	 CC	 admission	 were	 not	affected	by	social	deprivation	(Table	1).	
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Table	1.	Demographics	and	comorbidity	of	patients	admitted	with	acute	pancreatitis	
	 	 Patients	coded	as	
ICD10	K85	
(acute	
pancreatitis,	AP)	
Patients	meeting	
definition	of	true	
AP	(tAP)	
Patients	meeting	
definition	of	
severe	AP	(sAP)	
Patients	with	
sAP	admitted	to	
critical	care	(CC)	
(a	subset	of	sAP)	
Patients	with	
sAP	not	admitted	
to	critical	care	(a	
subset	of	sAP	
that	died	without	
CC	admission)	
Patients	not	
meeting	
definition	of	sAP	
(nsAP)	
Comparison	of	nsAP	vs	
sAP	(statistical	
significance,	P-value;	χ2	
test	1	d.f.,	unless	
specified)	
Number	of	cases		 (N,	%	total	cases)	 3340	 2053	(61.5%)	 390	(11.7%)	 368	(11.0%)	 22	(0.7%)	 1663	(49.8%)	 	
	 (N,	%	tAP)	 	 	 390	(19.0%)	 368	(17.9%)	 22	(1.1%)	 1663	(81.0%)	 	
	 (N,	%	sAP)	 	 	 	 368	(94.4%)	 22	(5.6%)	 	 	
	 	 	 	 	 	 	 	 	
Gender	 	(N	female,	%	cases	within	
category)	
1578	(47.2%)	 1028	(50.1%)	 183	(46.9%)	 172	(46.7%)	 11	(50%)	 845	(50.8%)	 0.167		
Age	in	years	 mean	(SD)	 54.9	(18.5)	 55.8	(18.5)	 60.1	(18.0)	 59.2	(17.9)	 73.5	(13.5)	 54.8	(18.5)	 <0.001	
Body	mass	index	
(N	=	1466)	
median	(1st,	3rd	quartile)	 26.7	(22.7,	31.6)	 27.5	(23.0,	32.3)	 28.4	(23.3,	33.1)	 28.4	(24.1,	33.1)	 22.1	(18.9,	30.7)	 27.3	(22.9,	32.0)	 0.227	
	 	 	 	 	 	 	 	 	
Proxies	for	lifestyle	(from	
GP	records)	
(N	for	which	this	recorded,	
%	total	cases)	
1657	(49.6%)	 1039	(50.6%)	 195	(50.0%)	 185	(50.3%)	 10	(45.6%)	 844	(50.8%)	 	
	 Overweight	 238	(14.4%)	 145	(14.0%)	 47	(24.1%)	 43	(23.2%)	 4	(40.0%)	 98	(11.6%)	 <0.001	
	 Prior/known	alcohol	
overuse	
64	(3.9%)	 33	(3.2%)	 13	(6.7%)	 12	(6.5%)	 1	(10.0%)	 20	(2.4%)	 0.002	
	 Smoking	 615	(37.1%)	 364	(35.0%)	 85	(43.6%)	 80	(43.2%)	 5	(50.0%)	 279	(33.1%)	 0.006	
	 	 	 	 	 	 	 	 	
Aetiology	of	AP	 (N	aetiology	recorded,	%)	 3340	(100%)	 2053	(100%)	 390	(100.0%)	 368	(100%)	 22	(100%)	 1663	(100%)	 	
		 gallstones	(N,	%	of	
recorded)	
1482	(44.4%)	 919	(44.8%)	 171(43.9%)	 	165(44.8%)	 6(27.3%)	 748(45.0%)	 0.686	
	 Alcohol	+	other	non-
gallstone*	(N,	%	of	
recorded)	
1877	(55.6%)	 1134(55.3%)	 219	(56.1%)	 203	(55.2%)	 16	(72.7%)	 915	(55.0%)	 	
	 	 	 	 	 	 	 	 	
Social	deprivation	quintile	 most	deprived	1	 1209	(36.4%)	 720	(35.3%)	 136	(35%)	 128	(34.9%)	 	 584	(35.4%)	 Between	groups	
	(N,	%	within	category)	 2	 704	(21.2%)	 412	(20.2%)	 79	(20.3%)	 72	(19.6%)	 	 333	(20.2%)	 0.971	(χ2	test	1	d.f.	trend)	
	 3	 543	(16.3%)	 327	(16%)	 66	(17%)	 65	(17.7%)	 	 261	(15.8%)	 	
	 4	 442	(13.3%)	 283	(13.9%)	 51	(13.1%)	 48	(13.1%)	 	 232	(14.0%)	 	
	 most	affluent	5	 424	(12.8%)	 299	(14.6%)	 57	(14.7%)	 54	(14.7%)	 	 242	(14.6%)	 	
`	 	 	 	 	 	 	 	 	
Duration	of	continuous	
inpatient	stay,	days	
median	(1st,	3rd	quartile)	 5	(3,	11)	 6	(3,	11)	 16	(9,	31)	 16	(10,	32)	 6	(2,	20)	 5	(3,	8)	 <0.001	(Wilcoxon)	*Exact	proportion	of	alcohol	diagnosis	not	possible	for	the	entire	cohort	–	see	text	for	discussion.			 	
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Healthcare	in	General	Practice	prior	to	study	episode	of	AP	The	GP	consultation	rate	in	the	year	preceding	the	index	AP	episode	was	higher	in	the	subset	of	patients	that	died	without	being	admitted	to	CC	than	those	patients	requiring	CC	or	those	that	did	not	develop	severe	AP	(Table	2).	25.6%	of	patients	with	an	episode	of	 tAP	 had	 a	 previous	 episode	 of	 AP	 recorded	 in	 their	 GP-held	 record,	 but	 a	 smaller	proportion	(18.5%)	of	those	with	sAP	had	a	previous	AP	episode	documented.	Although	the	aetiology	of	AP	could	be	attributed	to	gallstones	in	43%	of	patients,	gallstones	were	only	known	to	be	present	(in	advance	of	the	index	episode)	in	17.7%	of	those	with	tAP.	A	 similar	proportion	 (16.5%)	had	been	admitted	 to	hospital	 following	alcohol	misuse	prior	 to	 the	 index	 episode.	 The	 proportion	 with	 a	 prior	 episode	 of	 alcohol-related	hospital	admission	was	not	higher	in	the	sAP	group.	There	 was	 a	 greater	 baseline	 comorbidity	 burden	 amongst	 patients	 with	 sAP	compared	to	the	remainder	of	the	cohort.	Pre-existing	ischemic	heart	disease	(previous	MI	or	IHD/angina)	was	more	prevalent	in	those	with	sAP	needing	CC	admission	than	in	the	 tAP	 cohort	 as	 a	 whole	 (Table	 2).	 Pre-existing	 type	 2	 diabetes	 mellitus	 was	significantly	more	prevalent	in	those	with	sAP	requiring	CC	compared	to	the	tAP	cohort.	Similarly,	chronic	obstructive	pulmonary	disease,	hypertension,	and	renal	failure	(acute	and	 chronic)	 were	 significantly	 more	 prevalent	 among	 the	 sAP	 cohort	 requiring	 CC	admission	(Table	2).	The	following	classes	of	drug	were	prescribed	more	frequently	in	those	with	sAP	compared	 to	 the	 nsAP	 group:	 antidepressants,	 calcium-altering	 drugs,	 neuroleptic	agents,	oral	corticosteroids	and	statins.	The	proportions	of	patients	taking	each	class	of	drug	are	presented	in	Table	3.	Endoscopic	retrograde	cholangiopancreatography	(ERCP)	had	been	undertaken	in	 the	 preceding	 year	 in	 5.6%	 of	 those	 admitted	 with	 tAP.	 This	 proportion	 was	 not	higher	in	those	with	sAP.	Coronary	artery	stenting	had	been	performed	in	the	preceding	year	 more	 frequently	 in	 those	 with	 sAP	 requiring	 CC	 (3.0%)	 compared	 to	 the	 nsAP	cohort	(1.0%)	(Table	3).	
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Table	2.	Healthcare	prior	to	index	AP	admission	
	 	 Patients	coded	as	
ICD10	K85	(acute	
pancreatitis,	AP)	
Patients	meeting	
definition	of	true	
AP	(tAP)	
Patients	meeting	
definition	of	
severe	AP	(sAP)	
Patients		with	
sAP	admitted	to	
critical	care	
(sAP-CC)	
Patients	with	
sAP	not	
admitted	to	
critical	care	
Patients	not	
meeting	
definition	of	sAP	
(nsAP)	
Comparison	of	nsAP	
vs	sAP	(statistical	
significance,	P-value;	
χ2	test	1	d.f.,	unless	
specified)	
Number	of	cases		 (N,	%	total	cases)	 3340	 2053	(61.5%)	 390	(11.7%)	 368	(11.0%)	 22	(0.7%)	 1663	(49.8%)	 	
Patients	attending	GP	in	
year	prior	to	admission	
(N,	%	total	cases)	 618	(18.5%)	 317	(15.4%)	 48	(12.3%)	 42	(11.4%)	 	6	(27.3%)	 269	(16.2%)	 	
Number	of	GP	visits	in	year	
prior	to	admission	(GP	
attendees	only)		
median	(1st,	3rd	quartile)	 5	(2,	11)	 5	(2,	10)	 7	(3,	13)	 5	(2,	12)	 12	(7,	18)	 5	(2,	9)	 0.075(Mann-Whitney	U-test)	
A&E	attendances	in	year	
prior	to	admission	
median	(1st,	3rd	quartile)	 1	(1,	3)	 1	(1,	2)	 1	(1,	2)	 1	(1,	2)	 2	(1,	4)	 1	(1,	2)	 0.745	(Mann-Whitney	U-test)	
Hospital	inpatient	stays	in	
year	prior	to	admission	
median	(1st,	3rd	quartile)	 1	(0,	2)	 1	(0,	3)	 1	(0,	2)	 1	(0,	2)	 2	(0,	4)	 1	(0,	2)	 0.119	(Mann-Whitney	U-test)	
Hospital	outpatient	visits	
in	year	prior	to	admission	
median	(1st,	3rd	quartile)	 1	(0,	3)	 1	(0,	3)	 1	(0,	3)	 1	(0,	3)	 1	(0,	2)	 1	(0,	3)	 0.202	(Mann-Whitney	U-test)	
Number	of	previous	
admissions	with	AP	
median	(1st,	3rd	quartile)	 2	(1,	3)	 1	(1,	2)	 1	(1,	2)	 1	(1,	3)	 1	(1,	2)	 1	(1,	3)	 0.045	(Mann-Whitney	U-test)	
Previous	diagnoses	or	
admissions	
Acute	pancreatitis	 968	(29.0%)	 525	(25.6%)	 72	(18.5%)	 71	(19.3%)	 1	(4.5%)	 453	(27.2%)	 <0.001	
(N,	%	within	category)	 Gallstones	 628	(18.8%)	 364	(17.7%)	 61	(15.6%)	 58	(15.8%)	 2	(13.6%)	 303	(18.2%)	 0.230	
	 Alcohol-related	psychiatric	
admission	
757	(22.7%)	 338	(16.5%)	 59	(15.1%)	 56	(15.2%)	 3	(13.6%)	 279	(16.8%)	 0.429	
	 Hypertension	 942	(28.2%)	 595	(29.0%)	 152	(39.0%)	 143	(38.9%)	 9	(40.9%)	 443	(26.6%)	 <0.001	
	 Ischemic	heart	disease	 539	(16.1%)	 334	(16.3%)	 102	(26.2%)	 95	(25.8%)	 7	(31.8%)	 232	(14.0%)	 <0.001	
	 Myocardial	infarction	 223	(6.7%)	 146	(7.1%)	 48	(12.3%)	 45	(12.2%)	 3	(13.6%)	 98	(5.9%)	 <0.001	
	 Stroke	or	TIA	 226	(6.8%)	 139	(6.8%)	 41	(10.5%)	 38	(10.3%)	 3	(13.6%)	 98	(5.9%)	 0.001	
	 Hypercholesteremia	 197	(5.9%)	 125	(6.1%)	 21	(5.4%)	 21	(5.7%)	 0	 104	(6.3%)	 0.518	
	 DM	type	2	not	on	insulin	 471	(14.1%)	 267	(13.0%)	 79	(20.3%)	 79	(21.5%)	 0	 188	(11.3%)	 <0.001	
	 DM	type	2	treated	with	insulin	 57	(1.7%)	 20	(1.0%)	 6	(1.5%)	 5	(1.4%)	 1	(4.5%)	 14	(0.8%)	 0.208	
	 Diabetes	mellitus	(DM)	type	1	 113	(3.4%)	 45	(2.2%)	 9	(2.3%)	 9	(2.4%)	 0	 36	(2.2%)	 0.862	
	 DM	(unspecified)	 124	(3.7%)	 66	(3.2%)	 19	(4.9%)	 18	(4.9%)	 1	(4.5%)	 47	(2.8%)	 0.039	
	 Asthma	 345	(10.3%)	 198	(9.6%)	 45	(11.5%)	 43	(11.7%)	 2	(9.1%)	 153	(9.2%)	 0.159	
	 COPD	 313	(9.4%)	 180	(8.8%)	 47	(12.1%)	 40	(10.9%)	 7	(31.8%)	 133	(8.0%)	 0.011	
	 Chronic	kidney	disease	 247	(7.4%)	 150	(7.3%)	 49	(12.6%)	 45	(12.2%)	 4	(18.2%)	 101	(6.1%)	 <0.001	
	 Acute	kidney	disease	 114	(3.4%)	 62	(3.0%)	 20	(5.1%)	 16	(4.3%)	 4	(18.2%)	 42	(2.5%)	 0.007	
	 Renal	Dialysis	 16	(0.5%)	 7	(0.3%)	 3	(0.8%)	 3	(0.8%)	 0	 4	(0.2%)	 0.107	
	 Chronic	liver	disease	 277	(8.3%)	 119	(5.8%)	 20	(5.1%)	 19	(5.2%)	 1	(4.5%)	 99	(6.0%)	 0.530	
	 Cystic	Fibrosis	 2	(0.1%)	 1	(0.0%)	 0	(0.0%)	 0	(0.0%)	 0	 1	(0.1%)	 0.628	
	 Abdominal	trauma	 5	(0.1%)	 1	(0.0%)	 0	(0.0%)	 0	(0.0%)	 0	 1	(0.1%)	 0.628	
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Table	3.	Prescription	medications	and	procedures	
	 	 Patients	coded	as	
ICD10	K85	(acute	
pancreatitis,	AP)	
Patients	meeting	
definition	of	true	
AP	(tAP)	
Patients	meeting	
definition	of	
severe	AP	(sAP)	
Patients	
admitted	to	
critical	care		
(a	subset	of	
sAP)	
Patients	with	sAP	
not	admitted	to	
critical	care	(a	
subset	of	sAP)	
Patients	not	
meeting	
definition	of	sAP	
(nsAP)	
Χ2		test	of		sAP	vs.	
nsAP	
p-value	
Number	of	cases		 (N,	%	total	cases)	 3340	 2053	(61.5%)	 390	(11.7%)	 368	(11.0%)	 22	(0.7%)	 1663	(49.8%)	 	
Prescribed	drugs	in	year	up	
to	and	including	admission	
paracetamol	 1557	(46.6%)	 917	(44.7%)	 202	(51.8%)	 188	(51.1%)	 14	(63.6%)	 715	(43.0%)	 	
0.001	
(N,	%	within	category)	 antidepressants	 544	(16.3%)	 304	(14.8%)	 67	(17.2%)	 64	(17.4%)	 3	(13.6%)	 237	(14.3%)	 	0.137	
	 calcium-altering	drugs	 466	(14%)	 283	(13.8%)	 78	(20%)	 74	(20.1%)	 4	(18.2%)	 205	(12.3%)	 	
<0.001	
	 azathioprine	 26	(0.8%)	 17	(0.8%)	 4	(1%)	 4	(1.1%)	 0	 13	(0.8%)	 	0.629	
	 carbemazepine	 51	(1.5%)	 26	(1.3%)	 3	(0.8%)	 3	(0.8%)	 0	 23	(1.4%)	 	0.331	
	 oestrogens	 158	(4.7%)	 107	(5.2%)	 21	(5.4%)	 21	(5.7%)	 0	 86	(5.2%)	 	0.818	
	 neuroleptic	agents	 876	(26.2%)	 512	(24.9%)	 116	(29.7%)	 108	(29.3%)	 8	(36.4%)	 396	(23.8%)	 	
0.017	
	 oral	antidiabetic	agents	 247	(7.4%)	 144	(7%)	 33	(8.5%)	 32	(8.7%)	 1	(4.5%)	 111	(6.7%)	 	0.209	
	 oral	corticosteroids	 206	(6.2%)	 133	(6.5%)	 35	(9%)	 28	(7.6%)	 7	(31.8%)	 98	(5.9%)	 	0.025	
	 simvastatin	 625	(18.7%)	 402	(19.6%)	 110	(28.2%)	 107	(29.1%)	 3	(13.6%)	 292	(17.6%)	 	
<0.001	
	 statins	(excluding	
simvastatin)	
56	(1.7%)	 35	(1.7%)	 11	(2.8%)	 10	(2.7%)	 1	(4.5%)	 24	(1.4%)	 	0.058	
	 	 	 	 	 	 	 	 	
Procedures	in	year	up	to	and	
including	admission		
ERCP	 267	(8.0%)	 115	(5.6%)	 18	(4.6%)	 18	(4.9%)	 0	 97	(5.8%)	 	0.352	
(N,	%	within	category)	 Cholecystectomy	 254	(7.6%)	 142	(6.9%)	 19	(4.9%)	 18	(4.9%)	 1	(4.5%)	 123	(7.4%)	 	0.079	
	 Thyroid/parathyroid	surgery	 13	(0.4%)	 8	(0.4%)	 1	(0.3%)	 1	(0.3%)	 0	 7	(0.4%)	 	0.640	
	 Coronary	artery	stent	 40	(1.2%)	 27	(1.3%)	 11	(2.8%)	 11	(3.0%)	 0	 16	(1.0%)	 	
0.004	
	 Heart	valve	and/or	CABG	 15	(0.4%)	 9	(0.4%)	 1	(0.3%)	 1	(0.3%)	 0	 8	(0.5%)	 	0.547		
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Critical	care	admission	368/2053	(17.9%)	patients	with	tAP	were	admitted	to	critical	care	a	median	of	1	day	(IQR	0,	2)	after	admission	 to	hospital	 (Table	4).	The	5%	 trimmed	mean	 for	 this	 time	interval	was	1.8	days.	27.4%	of	patients	had	2	or	more	CC	admissions	 in	relation	to	1	episode	of	AP	and	6.2%	had	3	or	more	CC	admissions.	Median	(IQR)	duration	of	stay	for	the	 first	 CC	 admission	was	 68	 (27,	 139)	 hours.	 The	 duration	 of	 CC	 stay	 was	 slightly	longer	when	 averaged	 over	 all	 CC	 admissions	 (median	 72	 hours,	 IQR	 (29,	 156)),	 and	when	total	(sum)	CC	stay	was	calculated	for	any	one	individual	AP	episode	(i.e.	episodes	during	which	there	was	more	than	1	CC	stay),	the	median	(IQR)	duration	was	107	(45,	221)	 hours.	 An	 individual	 patient	 with	 AP	 requiring	 CC	 admission	 utilized	 6	 (3,	 11)	calendar	days	of	CC	care	(Table	5).	The	 median	 (IQR)	 APACHE-2	 score	 on	 admission	 to	 CC	 was	 19	 (14,	 24).	 The	number	of	organ	systems	requiring	support	is	presented	in	Table	4.	A	small	proportion	of	 sAP	 patients	 (24/368	 (6.5%)),	 were	 admitted	 for	 close	 observation	 without	 any	recorded	 organ	 support.	 During	 the	 initial	 admission,	 cardiovascular	 support	 with	vasopressors	was	used	in	60.3%	of	sAP	patients,	but	this	value	rose	to	65.5%	when	all	CC	 admissions	 were	 considered.	 13.9%	 required	 mechanical	 ventilation	 on	 the	 first	admission,	rising	to	18.1%	when	all	CC	admissions	for	that	AP	episode	were	considered.	4.8%	required	invasive	renal	replacement	therapy	at	any	point	during	CC	admission.	
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Table	4.	Admission	to	critical	care	
	 	 First	CC	
admission	
All	CC	
admissions	
CC	admissions	during	one	continuous	inpatient	stay	 1	or	more	 	 368	(100%)	
	 2	or	more	 	 101	(27.4%)	
	 3	or	more	 	 23	(6.2%)	
	 4	or	more	 	 5	(1.4%)	
	 5	 	 1	(0.0%)	
	 	 	 	
Days	from	hospital	admission	to	first	CC	admission	 mean	(95%	CI)	 3.03	(2.32,	3.74)	 	
	 5%	trimmed	mean	 1.83	 	
	 median	(1st,	3rd	quartile)	 1	(0,	2)	 	
	 	 	 	
APACHE	II	score	at	CC	admission	 median	(1st,	3rd	quartile)	 19	(14,	24)	 19	(14,	24)	
	 	 	 	
Organs	requiring	invasive	support	at	CC	admission	 0	 123	(33.4%)	 139	(27.9%)	
	 1	 124	(33.7%)	 162	(32.5%)	
	 2	 96	(26.1%)	 157	(31.5%)	
	 3	 22	(6%)	 36	(7.2%)	
	 4	 3	(0.8%)	 4	(0.8%)	
	 	 	 	
Organ	support	required	at	CC	admission	 No	immediate	organ	support	given	 24	(6.5%)	 26	(5.2%)	
	 	 	 	
Respiratory	 Facemask	/	nasal	cannulae	 296	(80.4%)	 382	(76.7%)	
	 O2	less	than	50%	 206	(56.0%)	 254	(51)	
	 O2	50%	or	more	 77	(20.9%)	 111	(22.3%)	
	 Continuous	positive	airway	pressure	 10	(2.7%)	 17	(3.4%)	
	 Endotracheal	tube	 46	(12.5%)	 85	(17.1%)	
	 Mechanical	ventilator	 51	(13.9%)	 90	(18.1%)	
	 Tracheostomy	 2	(0.5%)	 5	(1%)	
	 	 	 	
Cardiovascular	 Central	venous	catheter	 136	(37.0%)	 217	(43.6%)	
	 Arterial	line	 186	(50.5%)	 276	(55.4%)	
	 Inotropes/vasopressors	 222	(60.3%)	 326	(65.5%)	
	 Single	vasoactive/antiarrhythmic	drugs	 37	(10.5%)	 66	(13.3%)	
	 Multiple	vasoactive/antiarrhythmic	drugs	 15	(4.2%)	 21	(4.2%)	
	 Invasive	cardiac	output	monitoring	 10	(2.8%)	 16	(3.2%)	
	 Pulmonary	artery	catheter	 0	(0%)	 0	(0%)	
	 Oesophageal	doppler	waveform	analysis	 1	(0.3%)	 3	(0.6%)	
	 Peripheral	pulse	contour	analysis	 8	(2.2%)	 10	(2)	
	 other	method	 1	(0.3%)	 3	(0.6%)	
	 	 	 	
Renal	 Haemofiltration	/	dialysis	 17	(4.6%)	 24	(4.8%)	
	 	 	 	
Neurological	 Invasive	neurological	monitoring	 0	(0%)	 0	(0%)				 	
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Table	5.	Outcomes	in	critical	care	
	 	 1st	CC	period	 All	CC	periods	 Sum	of	CC	periods	in	one	
continuous	inpatient	stay	
Admitted	to	critical	care	(CC)	 Number	of	patients	 368	 498	 368	
Died	in	CC	 	 	 	 54	(14.7%)	
Hours	from	CC	admission	to	
death	
median	(1st,	3rd	quartile)	 	 	 70	(25,	371)	
	 mean	 	 	 260	
Hours	from	hospital	admission	
to	death	
median	(1st,	3rd	quartile)	 	 	 82	(26,371)	
	 mean	 	 	 264	
	 	 	 	 	
Hours	in	CC	 median	(1st,	3rd	quartile)	 68	(27,	139)	 72	(29,	156)	 107	(45,	221)	
	 mean	 115	 132	 179	
Days	in	CC	 median	(1st,	3rd	quartile)	 4	(2,	7)	 4	(2,	7)	 6	(3,	11)	
	 mean	 6.14	 6.47	 8.76	
	 	 	 	 	
Ventilator-free	days	 median	(1st,	3rd	quartile)	 3	(2,	5)	 3	(2,	5)	 4	(2,	7)	
	 mean	 4.18	 4.01	 5.43	
Haemofiltration/dialysis	
(days)	
median	(1st,	3rd	quartile)	 0	(0,	0)	 0	(0,	0)	 0	(0,	0)	6	(3,	8)	on	dialysis		
	 mean	 0.94	 0.96	 1.30	8.1	on	dialysis	
	 	 	 	 	
Lowest	pO2	on	blood	gas	kPa	 median	(1st,	3rd	quartile)	 9.9	(8.1,	11.4)	 9.8	(8.2,	11.2)	 	
Highest	pO2	on	blood	gas	kPa	 median	(1st,	3rd	quartile)	 14.5	(11.2,	22.7)	 15.4	(11.4,	23.6)	 	
	 	 	 	 	
Lowest	pCO2	on	blood	gas	kPa	 median	(1st,	3rd	quartile)	 5.1	(4.4,	6.0)	 5.3	(4.5,	6.1)	 	
Highest	pCO2	on	blood	gas	kPa	 median	(1st,	3rd	quartile)	 5.4	(4.8,	6.2)	 5.7	(5.0,	6.7)	 	
	 	 	 	 	
Lowest	pH	on	blood	gas	 median	(1st,	3rd	quartile)	 7.28	(7.15,	7.38)	 7.28	(7.20,	7.37)	 	
Highest	pH	on	blood	gas	 median	(1st,	3rd	quartile)	 7.37	(7.29,	7.42)	 7.36	(7.27,	7.42)	 	
	 	 	 	 	
Highest	fiO2	recorded	%O2	 median	(1st,	3rd	quartile)	 80	(50,	100)	 90	(60,	100)	 	
	 	 	 	 	
Highest	creatinine	mmol/L	 median	(1st,	3rd	quartile)	 139	(91,	243)	 144	(80,	272)	 	
	 	 	 	 	
Highest	bilirubin	mmol/L	 median	(1st,	3rd	quartile)	 26	(15,	68)	 25	(14,	58)	 			 	
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Factors	predicting	sAP	(admission	to	critical	care	or	death)	The	results	of	the	logistic	model	predicting	sAP	in	those	with	tAP	are	given	in	Table	6.	A	lower	 calcium	 level	 (-0.1	 mmol/L)	 at	 admission	 significantly	 increased	 the	 odds	 of	developing	 sAP	 by	 17%	 (OR	 =	 1.17	 95%	CI	 1.08,	 1.26).	 Patients	 previously	 admitted	with	AP	were	less	likely	to	need	to	need	CC	admission	during	a	subsequent	admission	(OR	 =	 0.77,	 95%	 CI	 0.61,	 0.98	 for	 one	 previous	 visit).	 A	 history	 of	 angina	 or	 IHD	increased	odds	of	sAP	(OR	=	1.46	95%	CI	1.07	to	2.00),	as	did	hypertension	(OR	=	1.43	95%	CI	1.05	to	1.96),	 in	addition	to	a	primary	care	 flag	 for	alcohol	dependency	(OR	=	1.68	 95%	 CI	 0.83	 to	 3.41).	 There	 was	 a	 significant	 interaction	 of	 age	 with	 type	 2	diabetes.		Generally,	younger	patients	had	a	lower	odds	of	sAP	compared	to	those	aged	over	 80	 years,	 but	 for	 those	 aged	 30-39	 years	 with	 type	 2	 diabetes	 the	 odds	 were	significantly	increased	(OR	=	18.85	95%	CI	1.36	to	90.84).	The	odds	were	still	higher	for	those	with	type	2	diabetes	as	age	increased	but	lower	than	for	the	30-39	age	group.	The	AUROC	=	0.68	and	the	Hosmer-Lemeshow	test	was	non-significant.	
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Table	6.	Logistic	regression	of	factors	predicting	development	of	tAP	to	sAP	(critical	
care	admission	or	death	)			
Parameter	 Regression	Estimate†	 Std	Error	
Intercept	 2.499	 1.069	
T2	DM	No	Insulin	(Y/N)	 -0.298	 0.442	
Simvastatin	12	Months	Prior	(Y/N)	 0.221	 0.151	
Number	of	prior	AP	Emergency	adm	(+	1	adm)		 -0.259	 0.123	
Angina	or	IHD	(Y/N)	 0.379	 0.161	
Hypertension	(Y/N)	 0.360	 0.161	
Test	Result	Calcium*	at	Index	Admission	(-0.1	
mmol/L)	 0.156	 0.038	
	
	
Age	group	(vs	80+)	
	 	 	
18-19	 -0.386	 0.780	
20-29	 -0.867	 0.630	
20-29	*	T2	DM	(Y/N)	 1.235	 1.279	
30-39	 -0.879	 0.614	
30-39*	T2	DM	(Y/N)	 2.936	 0.802	
40-49	 1.053	 0.608	
40-49	*	T2	(Y/N)	 0.643	 0.686	
50-59	 -0.342	 0.596	
50-59	*	T2	(Y/N)	 0.292	 0.576	
60-79	 -0.466	 0.591	
60-79	*	T2	(Y/N)	 0.890	 0.487	
Alcohol	flag*	(Y/N)	 0.521	 0.360	*19%	missing	calcium,	35%	missing	alcohol;	98%	relative	efficiency	of	multiple	imputations	with	10	imputations	†Increase	in	logodds		 	
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Mortality	Overall	 in-hospital	 mortality	 was	 defined	 for	 tAP	 patients	 only	 and	 was	 102/2053	(5.0%).	Overall	90-day	mortality	 for	the	tAP	cohort	was	127/2053	(6.2%)	and	for	the	sAP	 cohort	 was	 100/390	 (25.6%).	 In-hospital	 mortality	 amongst	 sAP	 admitted	 to	critical	 care	 was	 80/368	 (21.7%),	 of	 whom	 54/368	 (14.7%)	 died	 in	 CC	 and	 26/368	(7.1%)	died	in	hospital	after	discharge	from	CC	(Table	5).	Patients	who	 died	 in	 CC	 died	 after	 a	median	 (1st,	 3rd	 quartile)	 of	 70	 (25,	 371)	hours	after	CC	admission	(Table	5).	The	median	time	from	hospital	admission	to	death	for	 those	 dying	 in	 CC	was	 82	 (26,371)	 hours,	 from	which	 it	 can	 be	 inferred	 that	 the	median	time	between	admission	to	hospital	and	admission	to	CC	was	12	hours	(Table	
5).	Patients	who	died	 in	hospital	 after	discharge	 from	CC	died	after	a	median	 (1st,	 3rd	quartile)	of	9.9	(5.1,	21.9)	days	and	mean	23.0	days	after	CC	admission.	22	patients	with	sAP	died	in	hospital	without	being	admitted	to	critical	care	after	a	median	 (1st,	3rd	quartile)	of	4.5	 (2.0,	18.0)	days	and	mean	of	12.0	days.	The	specific	reasons	why	patients	with	severe	AP	in	this	subgroup	were	not	admitted	to	CC	are	not	known.	 None	 of	 these	 patients	 had	 advanced	 malignancy	 recorded	 as	 a	 cause	 or	contributor	on	their	death	certificate.	As	a	surrogate	to	identify	nursing	home	residents	who	may	not	have	been	suitable	for	critical	care,	we	examined	place	of	residence.		All	22	were	admitted	from	private	residence	rather	than	a	nursing	home	and	2/22	lived	alone.	Because	 pre-hospital	 and	 early	mortality	 in	 severe	 AP	 is	 greater	 in	 rural	 areas21,	 we	examined	postcodes	for	this	patient	subgroup.	20/22	were	from	urban	postcodes.	The	mean	±	SD	age	of	these	22	patients	was	74	±14	years	and	median	(range)	72	(46	to	92)	years.	The	median	BMI	 (1st,	3rd	quartile)	 for	 these	22	patients	was	significantly	 lower	(22.1	(18.9,	30.7))	than	the	respective	measures	for	the	remainder	of	the	tAP	cohort.		
Risk	of	death	after	critical	care	admission	The	results	of	fitting	the	parametric	Gamma	model	(lowest	AIC)	are	shown	in	Table	7	and	 Figure	2.	 Generally	 negative	 regression	 coefficients	 indicate	 factors	 that	 shorten	the	time	to	death.	The	only	factor	that	was	positive	was	T2	DM,	which	gave	a	time	ratio	of	2.99	(95%	CI	0.42,	21.28).	This	indicates	that	the	time	to	death	was	three-fold	longer	in	those	with	T2	DM.		There	were	very	significant	associations	of	shortening	of	time	to	death	 with	 thyroid	 /	 parathyroid	 history	 (TR	 =	 0.003	 95%	 CI	 0.001	 to	 0.012)	 and	
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history	of	CV	stent	in	previous	year	(TR		=	0.049	95%	CI	0.014	to	0.168).	For	each	unit	increase	 in	APACHE	 II	 score	 there	was	 a	 29%	 reduction	 in	 time	 to	 death	 (TR	=	 0.71,	95%	CI	 0.48	 to	 1.05),	while	 for	 each	 additional	 prior	CC	 admission	 the	 time	 to	death	reduced	by	34%	(TR	=	0.66	95%	CI	0.37	to	1.19).	Finally	for	each	increase	in	age	by	one	year	 the	 time	 to	death	 reduced	by	4%	 (TR	=	0.96	95%	CI	0.92	 to	1.01).	 Probabilities	estimated	 from	 the	 Gamma	model	 were	 very	 close	 to	 the	 Kaplan-Meier	 estimates	 of	survival.	
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Table	7.	Factors	that	impact	on	time	to	death	following	critical	care	from	a	Gamma	prediction	
model			
Parameter	 Regression	
Estimate*	
Standard	
Error	
95%	Confidence	Limits	 Chi-Square	 p-value	
	
Intercept	 10.006	 1.752	 6.572	 13.440	 32.61	 <.0001	
Age	at	index	admission	(+1	year)	 -0.037	 0.022	 -0.080	 0.006	 2.83	 0.093	
T2	DM		(Y/N)	 1.095	 1.001	 -0.867	 3.058	 1.20	 0.274	
Log	(APACHE	II)	(+	1	unit)	 -0.345	 0.200	 -0.736	 0.046	 2.99	 0.084	
CV	stent	within	1year	(Y/N)	 -3.015	 0.628	 -4.245	 -1.785	 23.08	 <.0001	
Thyroid/parathyroid	(Y/N)	 -5.875	 0.746	 -7.336	 -4.414	 62.10	 <.0001	
Number	of		CC	Stays	in	previous	year	(+	
1	CC	stay	
-0.414	 0.299	 -1.000	 0.172	 1.92	 0.166	
Gamma	Scale	parameter	 0.326	 0.053	 0.238	 0.448	 		 		
Gamma	Shape	parameter	 6.816	 1.093	 4.673	 8.958	 		 		*Log	of	time	to	death	ratio	(negative	represents	a	shorter	time	to	death)					
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Discussion	Acute	 pancreatitis	 is	 associated	 with	 a	 high	 mortality,	 shortens	 overall	 life	expectancy	in	survivors22	and	constitutes	a	considerable	healthcare	resource	burden7-9	13.	Specifically,	the	evolution	of	persistent	organ	dysfunction	requiring	critical	care	(CC)	support	has	the	most	deleterious	short	and	long	term	consequences	in	AP.	Building	on	previous	 work	 by	 others23	 24,	 in	 this	 cross-sectional	 observational	 study,	 we	 have	brought	together	sixteen	electronic	healthcare	records	into	a	single	national	Safe	Haven	overseen	by	the	Farr	Institute	governance	structure	to	conduct	a	detailed	study	of	the	development	of	organ	dysfunction	and	CC	admission	in	AP.	These	 data	 confirm	 a	 disproportionately	 high	 incidence	 of	 AP	 in	 the	 most	multiply	deprived	quintiles	of	areas,	 in	keeping	with	previous	observations	by	us	and	others25,	and	that	CC	admission	during	an	episode	of	AP	has	a	high	(21.7%)	mortality	compared	to	that	of	the	overall	cohort	(5.0%).	Patients	who	require	CC	admission	do	so	early	 in	 the	 disease	 course	 (at	 a	median	 of	 1	 day	 after	 admission)	 and	 experience	 a	median	total	of	6	days	CC	support	per	episode	of	AP.	Factors	independently	predictive	of	 CC	 admission	 or	 death	 include	 a	 history	 of	 angina,	 pre-existing	 hypertension,	hypocalcaemia,	 fewer	 prior	 emergency	 admissions	 with	 AP,	 and	 type	 2	 diabetes	 in	young	patients.	The	reasons	for	the	association	with	young	persons	with	type	2	diabetes	has	not	been	ascertained	from	our	data,	despite	our	efforts	to	do	so;	it	is	possible	that	this	observation	may	reflect	differences	in	older	persons,	or	reflect	a	confounder	in	our	dataset	that	we	have	been	unable	to	uncover.	Once	admitted	to	CC,	factors	predictive	of	death	 included	cardiovascular	 stenting	and	 thyroid	or	parathyroid	 surgery	within	 the	previous	year.	The	 overall	mortality	 seen	 in	 our	 study	 is	 comparable	with	 that	 seen	 in	 other	large	epidemiological	studies	in	the	UK26,	the	US7	8,	Taiwan2,	Japan4	and	South	Africa27.	The	mortality	in	the	population	of	patients	with	tAP	requiring	CC	in	the	present	cohort	is	 somewhat	 higher	 than	 many	 other	 reported	 studies,	 and	 certainly	 the	 APACHE-II	score	on	admission	to	CC	was	higher	than	the	average	for	the	general	ICU	population	in	the	Scottish	system28.	Patients	admitted	to	CC	who	subsequently	died	were	admitted	to	CC	sooner	(median	12	hours,	mean	14	hours)	after	hospital	admission	than	the	overall	5%	 trimmed	mean	 for	 overall	 sAP-CC	 cohort	 of	 1.83	 days	 (Table	4).	 Therefore,	 non-survivors	were	admitted	to	CC	sooner	after	hospital	admission	than	eventual	survivors.	
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It	 is	 likely	 that	 this	 is	 a	 consequence	 of	 more	 severe	 AP	 in	 non-survivors	 triggering	earlier	CC	admission	criteria.	A	second	alternative	explanation	is	that	it	is	possible	that	a	faster	evolution	variant	of	AP	 is	more	 lethal,	or	 that	 this	subgroup	of	patients	 is	more	susceptible	to	rapid	evolution	of	disease.	Lastly,	this	observation	may	reflect	a	delay	in	presentation	to	hospital	leading	to	increased	mortality	in	those	not	presenting	promptly	for	treatment.		Independent	predictors	of	severe	disease	in	tAP	included	a	history	of	angina	and	hypertension.	It	is	logical	that	patients	with	pre-existing	chronic	heart	disease	would	be	at	increased	risk	of	death	once	they	develop	organ	dysfunction,	and	this	is	borne	out	in	our	study	by	the	association	between	coronary	stenting	in	the	preceding	year	and	risk	of	 death	 after	 CC	 admission.	However,	 it	 is	 not	 as	 straightforward	 to	 link	 angina	 and	hypertension	with	an	increased	likelihood	of	needing	CC	admission	in	the	context	of	an	AP	 episode.	 Angina	 and	 hypertension	 in	 this	 scenario	may	 be	 confounders,	 acting	 as	surrogate	markers	of	other	chronic	health	conditions	that	directly	reduce	the	threshold	for	 developing	 organ	 dysfunction	 requiring	 CC,	 or	 they	 may	 indicate	 a	 lack	 of	physiological	 compensatory	 reserve	 in	 critical	 illness,	 such	 that	 for	 a	 given	inflammatory	insult	there	is	greater	physiological	derangement.		Our	observation	 that	a	higher	number	of	previous	admissions	with	AP	reduces	the	 risk	 for	 CC	 admission	 or	 death	 during	 a	 subsequent	 AP	 episode	 is	 novel.	 It	 is	uncertain	 whether	 this	 is	 a	 result	 of	 increased	 individual	 likelihood	 of	 developing	systemic	organ	dysfunction	with	particular	severity	of	inflammatory	insult,	or	whether	frequent	 A&E	 attenders,	 particularly	 with	 regard	 to	 alcohol	 overuse	 represent	 a	different	subset	of	patients.	The	 relationship	 between	 fluctuations	 in	 serum	 calcium	 and	 pancreatitis	 is	known29	and	the	association	between	thyroid	and	parathyroid	surgery	and	death	after	CC	admission,	and	between	hypocalcemia	and	calcium-altering	drugs	is	not	surprising.	Hypo-	or	hypercalcemia	is	recognized	in	both	the	Imrie30	and	Ranson31	scoring	systems,	and	there	is	a	wealth	of	preclinical	experimental	evidence	of	deranged	calcium	signaling	as	a	mechanism	of	pancreatic	acinar	cell	injury32.	
Strengths	of	study	The	 main	 strength	 of	 this	 study	 is	 the	 coalition	 of	 multiple	 electronic	 data	 sources	linked	though	a	unique	identifier	on	a	national	basis.	Critical	to	this	process	was	strict	
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data	protection.	This	was	achieved	through	the	use	of	a	centralized	protected	safe	haven	and	minimizing	the	number	of	individuals	with	access	to	the	non-anonymised	primary	data.	Furthermore,	industry	partners	could	be	fully	involved	in	the	protocol	design	and	processes	surrounding	the	data	collection	and	depository	without	needing	sight	of	any	primary	data.	Combining	detailed	 inpatient	CC	 information	collected	at	high	 temporal	resolution	 and	 integrating	 this	with	 broad	 background	data	 derived	 from	 community	data	sources	was	achieved.	
Limitations	and	Bias	Limitations	of	 this	study	 include	an	 inability	to	gain	 information	 in	electronic	 form	on	routinely	recorded	clinical	data	from	those	inpatients	that	did	not	require	CC.	This	may	have	 led	to	negative	reporting	bias	 for	events	that	might	be	relevant	to	this	study	but	not	 sufficiently	 severe	 to	 necessitate	 CC	 admission.	 In	 addition,	 we	 are	 unable	 to	ascertain	 exactly	how	many	 individuals	might	have	met	 criteria	 for	CC	admission	but	not	admitted	due	to	advance	directives	or	limited	capacity.	A	further	limitation	inherent	to	the	study	design	based	on	routinely	collected	data	is	the	relative	lack	of	confirmation	of	 the	 accuracy	 of	 source	 data	 entry.	 Although	 we	 specifically	 conducted	 a	 coding	accuracy	pilot	for	the	diagnosis	of	AP,	comparing	electronic	records	with	hand-written	notes	 in	 four	 separate	 study	 sites,	 and	while	 certain	 variables	 are	 likely	 to	 be	 highly	accurate,	 for	 example	 automatically-retrieved	 Wardwatcher™	 critical	 care	 data,	laboratory	 values	 and	 date	 of	 death	 on	 death	 certificates,	 certain	 other	 fields	 are	impossible	 to	 ratify	 accurately.	 We	 include	 in	 the	 latter	 category	 comorbidity	 and	clinical	information	recorded	in	hospital	discharge	summaries.		
Conclusions	National	record-linkage	analyses	from	a	wide	variety	of	routinely	collected	primary	and	secondary	 care	 data	 sources	 are	 feasible	 and	 constitute	 a	 powerful	 resource.	 Factors	that	 predict	 sAP	 are	 distinct	 from	 those	 that	 prognosticate	 mortality.	 Mortality	 in	patients	with	AP	who	require	CC	admission	remains	high.	
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Figure	1.	CONSORT	flow	diagram
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Figure	2.	Probability	(95%	CI)	plot	for	the	Gamma	model	
